Quantitative analysis revealed a 9.4-fold rise in CD3+CD8+ T cell numbers in SA-treated tumors relative to PBS controls (P < 0.001), with enhanced distribution extending from peritumoral regions into the tumor parenchyma (Figure 5B). The gene discussed is CD8A; the disease is neoplasm.